Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4073
Source ID: NCT02528396
Associated Drug: Biochaperone Insulin Lispro
Title: To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 1 Diabetes Mellitus
Interventions: DRUG: BioChaperone insulin lispro|DRUG: Humalog®
Outcome Measures: Primary: AUCΔBG0-2h (timepoint 0 = administration of the meal), Incremental area under the blood glucose (BG) concentration-time curve from 0-2 hours after a meal on day 1-3 \[comparison between treatments Biochaperone insulin lispro vs. lispro (Humalog®)\], 2 hours|AUClispro 0-30min (timepoint 0 = time of dosing), Area under the serum insulin lispro concentration-time curve from 0-30 minutes after bolus dose on one of days 1, 2 or 3 (comparison between treatments BioChaperone insulin lispro vs. lispro (Humalog®)), 30 minutes | Secondary: AUClispro_0-6h, Area under the serum insulin lispro concentration-time curve from 0-6 hours after bolus dose, 6 Hours|Cmax_lispro, Maximum serum insulin lispro concentration, up to 6 Hours|Tmax_lispro, Time to maximum observed serum insulin lispro concentration, up to 6 Hours|AUCBG_0-6h, Area under the curve under the blood glucose (BG) concentration time curve from 0-6 hours, 6 Hours|ΔBGmax, Maximum blood glucose (BG) excursion after a standard meal (0-6 hours), 6 Hours|Adverse events, Number of Adverse events, Up to 3 months|Local tolerability injection site reactions, Injection site reactions over 14 days of exposure, 14 days
Sponsor/Collaborators: Sponsor: Adocia | Collaborators: Eli Lilly and Company
Gender: ALL
Age: ADULT
Phases: PHASE1
Enrollment: 36
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2015-08
Completion Date: 2015-12
Results First Posted:
Last Update Posted: 2016-03-16
Locations: Profil GmbH, Neuss, 41460, Germany
URL: https://clinicaltrials.gov/show/NCT02528396